Radionetics Oncology is a clinical-stage radiopharmaceutical company focused on discovering and developing novel small molecule radiotherapeutics that target GPCRs for a wide range of oncology indications. The company is advancing a pipeline of potent small molecule radioligands aimed at cancers including adrenocortical carcinoma, breast cancer, and lung cancer. Radionetics plans to use proceeds from its recent financing to advance this pipeline and further develop its GPCR-targeted radiopharmaceutical candidates. The company spun out of Crinetics Pharmaceuticals and is supported by investors including Frazier Life Sciences, 5AM Ventures, DCVC Bio, Crinetics Pharmaceuticals, and GordonMD Global Investments. Radionetics recently completed a $52.5 million Series A, bringing total capital raised to date to $82.5 million. The company is based in San Diego and positions itself to be a leader in first-in-class radiopharmaceutical development.

Total raised

$53M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2024